###begin article-title 0
Genetic Manipulations of PPARs: Effects on Obesity and Metabolic Disease
###end article-title 0
###begin p 1
Recommended by Wallace Harrington
###end p 1
###begin p 2
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 2
###begin p 3
###xml 314 318 <span type="species:ncbi:10090">mice</span>
The interest in genetic manipulations of PPARs is as old as their discovery as receptors of ligands with beneficial clinical activities. Considering the effects of PPAR ligands on critical aspects of systemic physiology, including obesity, lipid metabolism, insulin resistance, and diabetes, gene knockout (KO) in mice is the ideal platform for both hypothesis testing and discovery of new PPAR functions in vivo. With the fervent pursuit of the magic bullet to eradicate the obesity epidemic, special emphasis has been placed on the impacts of PPARs on obesity and its associated diseases. As detailed in this review, understanding how PPARs regulate gene expression and basic metabolic pathways is a necessary intermediate en route to deciphering their effects on obesity. Over a decade and dozens of genetic modifications of PPARs into this effort, valuable lessons have been learned, but we are left with more questions to be answered. These lessons and future prospects are the subject of this review.
###end p 3
###begin title 4
###xml 7 12 7 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
1. PPARalpha
###end title 4
###begin p 5
###xml 43 48 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 228 229 224 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 236 241 232 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 407 408 399 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 410 411 402 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 445 450 437 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppara</italic>
###xml 585 586 577 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 739 740 731 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 742 743 734 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 944 949 936 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 423 427 <span type="species:ncbi:10090">mice</span>
###xml 604 608 <span type="species:ncbi:10090">mice</span>
The only PPAR faithful to its acronym, PPARalpha, is the nuclear receptor of peroxisome proliferators-a diverse group of compounds, which in addition to toxic and carcinogenic chemicals include the lipid-lowering fibrate drugs [1]. PPARalpha is expressed in active metabolic tissues, including liver, heart, brown fat, and skeletal muscle, where it regulates genes that catalyze fatty acid (FA) catabolism [1, 2]. By 1995, mice homozygous for a Ppara-null allele were generated and found to be viable, healthy, fertile, and devoid of gross phenotypic defects under standard husbandry [3]. However, these mice could mount neither the hepatic response to peroxisome proliferators nor the induction of lipid-metabolizing enzymes by fibrates [3, 4]. These results confirmed the null nature of this allele, and obviated the need for alternative null configurations; consequently, this strain has become the exclusive animal model for studies of PPARalpha deficiency to date. These studies are summarized below.
###end p 5
###begin title 6
1.1. Ppara KO and obesity
###end title 6
###begin p 7
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppara</italic>
###xml 188 189 188 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 190 191 190 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 219 224 219 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 385 386 381 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 422 427 418 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 524 525 516 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 527 528 519 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 606 611 598 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppara</italic>
###xml 611 614 603 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 621 622 613 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 810 815 802 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 28 32 <span type="species:ncbi:10090">mice</span>
###xml 309 313 <span type="species:ncbi:10090">mice</span>
###xml 615 619 <span type="species:ncbi:10090">mice</span>
Early studies of Ppara-null mice reported hepatosteatosis and elevated levels of circulating triglycerides (TG) and cholesterol, as well as a significant increase in gonadal fat pad mass [5-8]. The integral role of PPARalpha in body fat mass determination is further cemented by the demonstration that the KO mice fail to decrease adipose tissue weight in response to hyperleptinemia [9]. However, the contribution of PPARalpha to total body weight is ambiguous, with conflicting reports of substantial age-related obesity [6, 7] versus no significant body weight effects in congenic 129/SvJae or C57BL/6N Ppara-/- mice [8]. The discrepant outcomes of these studies have been attributed to subtle experimental variations in the genetic background and chow composition, and suggest that the contribution of PPARalpha to obesity is strongly influenced by genomic and environmental contexts.
###end p 7
###begin title 8
1.2. Ppara KO and fasting
###end title 8
###begin p 9
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppara</italic>
###xml 228 233 228 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppara</italic>
###xml 341 346 341 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 546 548 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 549 551 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 835 837 831 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 839 841 835 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 848 853 844 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 993 995 985 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 1048 1053 1040 1041 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 1082 1087 1070 1075 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppara</italic>
###xml 1241 1243 1229 1231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1245 1247 1233 1235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 1280 1285 1268 1269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 1457 1462 1441 1446 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppara</italic>
###xml 1522 1524 1506 1508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 1575 1580 1559 1564 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppara</italic>
###xml 1774 1776 1758 1760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 1846 1851 1830 1831 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 1987 1992 1967 1968 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 2043 2045 2019 2021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 2058 2067 2034 2043 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MHC-Ppara</italic>
###xml 2260 2262 2236 2238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 45 49 <span type="species:ncbi:10090">mice</span>
###xml 1468 1472 <span type="species:ncbi:10090">mice</span>
###xml 1586 1590 <span type="species:ncbi:10090">mice</span>
###xml 2068 2083 <span type="species:ncbi:10090">transgenic mice</span>
The relatively minor phenotype of Ppara-null mice under standard husbandry conditions is consistent with a contingency function that comes into play under metabolic duress. Accordingly, multiple studies addressed the ability of Ppara-null to cope with dietary challenges. The most informative manipulation has been fasting, during which PPARalpha deficiency was shown to cause excessive surge in circulating FA levels, rapid hepatic and cardiac lipid accumulation, absent ketogenic response, profound hypoglycemia and hepatic glycogen depletion [10-13]. These anomalies are thought to arise from failure of the mutant livers to catabolize adipose tissue-derived FA, which on the one hand impairs gluconeogenesis at both enzyme activity and substrate levels, and on the other hand leads to morbid accumulation of nonmetabolized lipids [14, 15]. PPARalpha is similarly critical for cardiac lipid oxidation, which is the main energy source for the heart during fasting and exercise; reviewed in [16]. Both constitutive and inducible expression of PPARalpha target genes are blunted in Ppara-null hearts, which exhibit abnormal TG accumulation during fasting and progressive deterioration of myofibrillar and mitochondrial integrity upon aging [10, 17]. The crucial importance of PPARalpha-mediated hepatic and cardiac lipid catabolism, regardless of fasting, is also evident in the severe hypoglycemia and staggering lipid accumulation in livers and hearts of Ppara-null mice following pharmacological inhibition of FA flux [18]. Interestingly, female and estrogen-treated male Ppara-null mice are significantly protected against this lethal combination of tissue hyperlipidemia and systemic hypoglycemia, implying an alternative, estrogen-dependent lipid utilization pathway [18]. While proper cardiac metabolism is disrupted in the absence of PPARalpha, dosage and temporal regulation of the receptor are critical, and its constitutive transgenic overexpression in cardiac muscle via the alpha myosin heavy chain (MHC) promoter is detrimental [19]. Hearts of MHC-Ppara transgenic mice exhibit a faithful phenocopy of diabetic cardiomyopathy, with increased lipid oxidation, a reciprocal decrease in glucose utilization, and symptoms of ventricular hypertrophy [19].
###end p 9
###begin title 10
1.3. Ppara KO in high-fat and cholesterol-rich diets
###end title 10
###begin p 11
###xml 16 21 16 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 126 131 122 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppara</italic>
###xml 164 166 160 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</italic>
###xml 288 290 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 291 293 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 422 427 418 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppara</italic>
###xml 583 585 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 753 755 749 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</italic>
###xml 763 768 759 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppara</italic>
###xml 803 805 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 912 917 908 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppara</italic>
###xml 1152 1157 1148 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 1215 1220 1207 1208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 1371 1376 1359 1364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppara</italic>
###xml 1510 1515 1498 1503 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppara</italic>
###xml 1664 1666 1652 1654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 1730 1735 1718 1719 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 137 141 <span type="species:ncbi:10090">mice</span>
###xml 167 171 <span type="species:ncbi:10090">mice</span>
###xml 433 437 <span type="species:ncbi:10090">mice</span>
###xml 774 778 <span type="species:ncbi:10090">mice</span>
###xml 923 927 <span type="species:ncbi:10090">mice</span>
###xml 1382 1386 <span type="species:ncbi:10090">mice</span>
###xml 1521 1525 <span type="species:ncbi:10090">mice</span>
The role of PPARalpha in the physiological outcomes of high fat diet (HFD) is not as clear as its role in fasting physiology. Ppara-null mice are as susceptible as wt mice to HFD-induced weight gain and hepatic TG accumulation, but are protected from glucocorticoid-induced hypertension [20-22]. Blunted hyperinsulinemia and improved glucose and insulin tolerance following 2-hour fasting suggested initially that HFD-fed Ppara-null mice are protected from insulin resistance (IR) as a result of either reduced hepatic glucose production or increased peripheral insulin sensitivity [20]. However, this report has been contested by a study that found little difference in hyperinsulinemia and peripheral glucose uptake during euglycemic clamp of HFD-fed wt versus Ppara-null mice in the nonfasted state [23]. This contradictory result raised the concern that the improved insulin and glucose tolerance of HFD-fed Ppara-null mice in the earlier studies reflects no more than their established hypoglycemic response to the fasting regimen that preceded the assays; studies that bypass this conceptual hurdle will be required to reevaluate the role of PPARalpha in the aftermath of HFD. Because the consequences of PPARalpha deficiency also include a constitutive increase in circulating cholesterol, it is equally important to test the effects of a cholesterol-rich diet in Ppara-null mice. Surprisingly, addition of 2% cholesterol to the chow caused fat pad weight reduction and increased de novo lipogenesis in Ppara-null mice, indicating that the receptor participates in basal and feedback-regulated cholesterol and triacylglycerol homeostasis in adipose tissue [24]. These activities impinge directly on the contribution of PPARalpha to obesity.
###end p 11
###begin title 12
1.4. Effects of Ppara KO on other tissues
###end title 12
###begin p 13
###xml 25 30 25 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 54 59 50 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 228 233 220 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 235 237 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 282 287 270 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 467 469 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 696 701 680 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 796 801 776 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppara</italic>
###xml 887 892 867 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 894 896 870 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 935 940 911 912 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 979 981 951 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</italic>
###xml 1061 1066 1033 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 1093 1095 1061 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 1114 1119 1082 1087 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppara</italic>
###xml 1256 1261 1224 1225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 367 371 <span type="species:ncbi:10090">mice</span>
###xml 807 811 <span type="species:ncbi:10090">mice</span>
###xml 982 986 <span type="species:ncbi:10090">mice</span>
###xml 1125 1129 <span type="species:ncbi:10090">mice</span>
Unlike the effect of PPARalpha on cardiac muscle, PPARalpha deficiency had no significant effect on the responses of skeletal muscle to either fasting or heavy exercise, perhaps due to compensation by redundant functions of PPARdelta [25]. However, transgenic overexpression of PPARalpha in skeletal muscle, using the muscle creatine kinase (MCK) promoter, protected mice from HFD-induced obesity, albeit at the expense of glucose intolerance and insulin resistance [26]. The proposed mechanism entails reduced insulin-stimulated glucose uptake due to repression of AMP-activated protein kinase-dependent glucose transporter gene expression by oxidized FA. The hepatocentric view of systemic PPARalpha effects is moderated by a recent report of increased peripheral glucose utilization in fasted Ppara-null mice, which was refractory to adenovirus-mediated reconstitution of hepatic PPARalpha [27]. Moreover, direct injection of a PPARalpha agonist into the lateral ventricle of wt mice significantly reduced whole body glucose utilization, suggesting that PPARalpha also functions centrally [27]. Tissue-specific Ppara-null mice, which have yet to be generated, would be an ideal platform to validate and further explore these intricate mechanisms of PPARalpha action.
###end p 13
###begin title 14
###xml 20 25 20 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
2. A PANOPLY OF PPARgamma KNOCKOUTS
###end title 14
###begin p 15
###xml 46 51 46 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 60 65 56 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 85 90 77 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 190 195 178 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 284 286 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 288 290 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 317 322 301 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 352 354 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 355 357 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 447 449 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 451 453 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 581 586 561 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 774 779 750 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 984 989 960 961 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 1067 1072 1039 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 625 629 <span type="species:ncbi:10090">mice</span>
###xml 730 735 <span type="species:ncbi:10090">mouse</span>
Without detracting from the importance of PPARalpha and PPARdelta (see below for PPARdelta), the defining moment in the explosive growth of the PPAR field has been the identification of PPARgamma as the high-affinity receptor of the insulin-sensitizing thiazolidinedione (TZD) drugs [28, 29]. The pivotal role of PPARgamma in the adipocyte life cycle [30-34], combined with the blockbuster success of its TZD ligands in treating type II diabetes [35, 36], generated widespread enthusiasm for the prospect of solving the causal relationship between obesity and diabetes through PPARgamma research. The use of gene knockout in mice presented the most logical investigative approach, leading to the generation of a dazzling array of mouse strains with genetic modifications of Pparg. This volume of effort reflects not only the immense biomedical significance of the gene, but also the complexity of the genetic data, which had encumbered immediate, straightforward understanding of PPARgamma function in vivo and had spawned numerous alternative hypotheses. The myriad Pparg KO strains, and the results of their analyses, are summarized below.
###end p 15
###begin p 16
###xml 95 100 95 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 174 176 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 216 218 212 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</italic>
###xml 236 241 232 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 260 262 256 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</italic>
###xml 299 301 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 323 328 319 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 425 434 421 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bona fide</italic>
###xml 545 547 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 595 600 591 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 697 702 689 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 771 776 763 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 849 851 841 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 853 855 845 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 942 947 934 939 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 971 973 963 965 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</italic>
###xml 1030 1038 1022 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt/Pparg</italic>
###xml 1084 1086 1076 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</italic>
###xml 1106 1111 1098 1103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 1184 1189 1176 1181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 1235 1237 1227 1229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</italic>
###xml 1269 1274 1261 1266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 1433 1441 1425 1433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt/Pparg</italic>
###xml 1480 1482 1472 1474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</italic>
###xml 1541 1543 1533 1535 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</italic>
###xml 1548 1553 1540 1545 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 1583 1585 1575 1577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 57 61 <span type="species:ncbi:10090">mice</span>
###xml 834 839 <span type="species:ncbi:10090">mouse</span>
###xml 953 957 <span type="species:ncbi:10090">mice</span>
Constitutive Pparg deficiency cannot be studied in adult mice due to the essential role of PPARgamma in placental development, which abolishes survival beyond mid-gestation [34]. However, aggregation with tetraploid wt embryos provided Pparg-null embryos with wt placentas and rescued them to term [34]. In these chimeras, Pparg-null cells committed to the adipocyte lineage, but failed to proliferate and differentiate into bona fide adipocytes, and a chimeric pup that survived a few days after birth was devoid of any type of adipose tissue [34]. This effort proved the essential role of PPARgamma in early adipogenesis in vivo, but unfortunately, perinatal lethality precluded studies of this Pparg-null configuration beyond birth. The current availability of floxed Pparg alleles (see below) and epiblast-specific Cre-expressing mouse strains [37, 38] should revitalize this configuration by facilitating higher throughput generation of Pparg-null mice supported by wt placentas. Studies in progress in our lab with standard wt/Pparg-null chimeras, in which diploid host-derived wt cells coexist with Pparg-null ES-derived cells, confirmed the formation and subsequent arrest of Pparg-null adipose tissue primordia. However, here wt cells infiltrated the stagnant Pparg-null primordia and repopulated them through a previously unknown developmental feedback mechanism (S. Kim and Y. Barak, unpublished). Consequently, post-term wt/Pparg-null chimeras invariably possess only wt adipose tissue, in contrast to the random contribution of wt and Pparg-null cells to other tissues [31].
###end p 16
###begin title 17
###xml 10 13 10 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 13 17 <span type="species:ncbi:10090">mice</span>
2.1. Pparg+/-mice
###end title 17
###begin p 18
###xml 5 14 5 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bona fide</italic>
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 84 89 84 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 151 156 151 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 191 196 187 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 196 199 192 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 252 257 248 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 302 304 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 440 445 432 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 445 448 437 440 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 487 489 479 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</italic>
###xml 539 541 531 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 542 544 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 621 626 613 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 916 921 904 905 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 1060 1065 1044 1045 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 1121 1126 1101 1102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 1194 1196 1170 1172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 1198 1200 1174 1176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 32 36 <span type="species:ncbi:10090">mice</span>
###xml 108 112 <span type="species:ncbi:10090">mice</span>
###xml 200 204 <span type="species:ncbi:10090">mice</span>
###xml 449 453 <span type="species:ncbi:10090">mice</span>
###xml 1105 1109 <span type="species:ncbi:10090">mice</span>
With bona fide adult Pparg-null mice unavailable, investigators initially turned to Pparg-haploinsufficient mice to explore the effects of reduced PPARgamma dosage. As expected, adiposity of Pparg+/- mice was reduced, supporting the assertion that PPARgamma contributes quantitatively to adipose mass [39]. However, contrary to the expectation that reduced levels of the TZD receptor will cause a parallel reduction in insulin sensitivity, Pparg+/- mice were more insulin-sensitive than wt controls when challenged by either HFD or aging [39-41]. This confounding observation conflicts with the monochromatic view of PPARgamma as a beneficial TZD-activated insulin sensitizer and raises the counterintuitive notion that it has pathogenic activities. While the nature of these adverse properties of the receptor is unclear, one potential example of a latent pathogenic effect is the positive relationship between PPARgamma dosage and adipose tissue mass, which might come into play under conditions of nutritional affluence. However, excessive reduction of PPARgamma activity by treating haploinsufficient mice with a PPARgamma antagonist reversed the tide and resulted in lipodystrophy and IR [42, 43].
###end p 18
###begin title 19
2.2. Tissue-specific Pparg KOs
###end title 19
###begin p 20
###xml 78 86 78 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cre-loxP</italic>
###xml 174 179 174 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 240 245 240 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 268 270 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 272 274 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 276 278 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 281 286 277 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 513 517 509 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
Tissue-specific Pparg KOs were subsequently developed by several groups using Cre-loxP methodology, with the vision of both bypassing the embryonic lethality of constitutive Pparg deficiency and resolving the physiological functions of PPARgamma one tissue at a time [32, 44, 45]. Pparg has since been deleted in a substantial number of cell types, of which the most pertinent to this review are adipocytes, myocytes, and hepatocytes, and from a broader metabolic disease perspective also macrophages, pancreatic beta-cells, renal collecting duct epithelia, and endothelial cells (referenced below).
###end p 20
###begin title 21
2.2.1. Adipocyte-specific Pparg KO
###end title 21
###begin p 22
###xml 31 36 31 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 296 301 292 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 401 406 393 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 523 528 511 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fabp4</italic>
###xml 582 587 570 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 636 641 620 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fabp4</italic>
###xml 722 727 706 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 771 776 751 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 787 789 767 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 791 793 771 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 851 856 831 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fabp4</italic>
###xml 951 953 931 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 1077 1082 1057 1062 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 1166 1168 1146 1148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 1170 1172 1150 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 1294 1296 1274 1276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 1501 1503 1481 1483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 1505 1507 1485 1487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 369 374 <span type="species:ncbi:10090">mouse</span>
###xml 993 997 <span type="species:ncbi:10090">mice</span>
###xml 1088 1092 <span type="species:ncbi:10090">mice</span>
The abundant expression of PPARgamma in adipocytes indicates that its important functions in these cells extend beyond its indispensability for their formation. Moreover, the association between obesity as well as type II diabetes and the antidiabetic effect of TZDs fuel the hypothesis that PPARgamma activity in adipocytes is a key to systemic insulin sensitivity. A mouse whose adipocytes lack PPARgamma would provide the ultimate test for this idea. Generation of such a model was attempted using an adipocyte-specific Fabp4(aP2)-CRE transgene. While, as mentioned earlier, PPARgamma is essential for adipocyte differentiation, the Fabp4 promoter is activated after completion of adipogenesis, and thus allows the PPARgamma-dependent formation of adipocytes prior to Pparg deletion [32, 45]. Contrary to a widespread, unsubstantiated concern, the Fabp4 promoter does not drive transgene expression in macrophages or other major metabolic tissues [32], and therefore the phenotype of these mice is not muddled by gene deletion in nonadipocyte cell types. Adipocyte-specific Pparg-null mice exhibited rapid loss of brown adipose tissue (BAT) and subcutaneous fat [32, 45]. Astonishingly, however, white adipose tissue (WAT) retained normal mass throughout a substantial stretch of adulthood [32]. This retention occurred despite substantial cell death and extensive fibrosis and inflammatory infiltration, and resulted from both overt hypertrophy of surviving adipocytes and adipocyte regeneration [32, 45].
###end p 22
###begin p 23
###xml 42 47 42 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 216 221 212 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 226 228 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 250 254 246 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">loxP</italic>
###xml 272 277 268 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 292 297 288 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fabp4</italic>
###xml 795 797 791 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 810 815 806 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 953 958 945 950 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 1088 1090 1080 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
###xml 1222 1227 1214 1215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 1264 1269 1252 1257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fabp4</italic>
###xml 1274 1279 1262 1267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 1279 1284 1267 1272 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 1327 1332 1315 1320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 1372 1374 1360 1362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</italic>
###xml 1480 1485 1468 1469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 1706 1708 1690 1692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 1710 1712 1694 1696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 1903 1905 1887 1889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 2215 2217 2199 2201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 2323 2325 2307 2309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 2445 2450 2429 2430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 2498 2503 2478 2483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 2575 2580 2555 2556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 176 180 <span type="species:ncbi:10090">mice</span>
###xml 237 241 <span type="species:ncbi:10090">mice</span>
###xml 528 532 <span type="species:ncbi:10090">mice</span>
###xml 1047 1051 <span type="species:ncbi:10090">mice</span>
###xml 1285 1289 <span type="species:ncbi:10090">mice</span>
###xml 1430 1434 <span type="species:ncbi:10090">mice</span>
###xml 1523 1527 <span type="species:ncbi:10090">mice</span>
###xml 1952 1956 <span type="species:ncbi:10090">mice</span>
###xml 2309 2313 <span type="species:ncbi:10090">mice</span>
###xml 2509 2514 <span type="species:ncbi:10090">mouse</span>
The tight dependence of adipocytes on PPARgamma for survival and the interpretation that adipocyte regeneration mitigates lipodystrophy were unequivocally proven by studies of mice with tamoxifen-inducible adipocyte Pparg KO [33]. These mice carry a loxP-flanked (floxed) Pparg allele and an Fabp4-driven fusion of Cre with a tamoxifen-responsive estrogen receptor mutant, which translocates to the adipocyte nucleus and targets the floxed allele only in response to tamoxifen administration. Induction of Cre activity in these mice induced synchronous, near-complete loss of white and brown adipocytes within 7 days, followed by acute inflammatory infiltration of the damaged fat pads, and complete rebound of adipocyte number and adipose tissue integrity within 6 weeks of the initial insult [33]. Thus, PPARgamma is essential for the survival of mature adipocytes, but a rapid and robust regenerative process mitigates a loss of fat tissue following Pparg deletion. Similar regenerative potential of adipose tissue was recently demonstrated in mice with inducible adipocyte apoptosis [46], buttressing the notion that fat regenerates with remarkable efficiency in response to adipocyte death, beyond the context of PPARgamma deficiency. Thus, adipose tissue of Fabp4-Cre Ppargfl/fl mice comprised a dynamic mixture of dying Pparg-null adipocytes alongside repopulating wt adipocytes-a condition that hindered the generation of mice with adipose tissue that uniformly lacks PPARgamma. As long as WAT was sustained, these mice maintained relatively normal lipid and glucose homeostasis, despite substantial reduction in circulating leptin and adiponectin and an anticipated rise in the levels of free FA [32, 45]. Moderate IR and glucose intolerance, as well as hepatomegaly, steatosis, and increased hepatic glucose production, developed only in conjunction with the eventual terminal atrophy of WAT [32]. Analyses of two independent stocks of these mice by two research teams found obvious resistance to HFD-induced obesity, likely due to the failure to accumulate adipocytes. However, the two teams observed opposite effects on insulin sensitivity. In one study, HFD accelerated lipoatrophy and exacerbated IR [32], whereas the other study found no such degenerative effect and the mutation protected the mice from IR [45]. In summary, while reproving the critical role of WAT in systemic insulin sensitivity and the indispensability of PPARgamma to adipocyte viability, the adipocyte-specific Pparg-null mouse fell short of a definitive demonstration that adipocyte PPARgamma regulates whole body metabolism.
###end p 23
###begin title 24
2.2.2. Myocyte-specific Pparg KO
###end title 24
###begin p 25
###xml 40 45 40 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 176 181 172 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 324 329 316 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 427 432 415 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 492 497 480 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 521 524 509 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MCK</italic>
###xml 701 703 689 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47">47</xref>
###xml 831 833 819 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</italic>
###xml 867 872 855 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 924 929 908 909 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 1030 1035 1010 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 1099 1104 1079 1080 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 1129 1131 1105 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B48">48</xref>
###xml 1176 1181 1152 1157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 1225 1228 1201 1204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MCK</italic>
###xml 1695 1700 1671 1672 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 2316 2321 2288 2289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 503 507 <span type="species:ncbi:10090">mice</span>
###xml 721 725 <span type="species:ncbi:10090">mice</span>
###xml 834 838 <span type="species:ncbi:10090">mice</span>
###xml 962 966 <span type="species:ncbi:10090">mice</span>
###xml 1389 1393 <span type="species:ncbi:10090">Mice</span>
###xml 2134 2138 <span type="species:ncbi:10090">mice</span>
The insulin sensitizing activity of PPARgamma ligands and the key role of skeletal muscle in peripheral insulin sensitivity generated great interest in the hypothesis that PPARgamma exerts its insulin sensitizing activity from within myocytes. However, this hypothesis was challenged by the very low basal expression of PPARgamma in skeletal muscle. The issue was addressed by two parallel studies that analyzed the outcome of Pparg deletion in myocytes. In the first study, myocyte-specific Pparg-null mice generated by MCK promoter-driven Cre recombinase exhibited increased adiposity, elevated susceptibility to HFD-induced weight gain, and marked hepatic IR in hyperinsulinemic-euglycemic clamps [47]. However, these mice were only as sensitive to HFD-induced IR and as responsive to the insulin sensitizing effects of TZDs as wt mice, suggesting that muscle PPARgamma is dispensable for the antidiabetic effects of PPARgamma agonists. The second study used mice generated using the same Cre transgene, but a different floxed Pparg allele, and first addressed the controversial issue of low PPARgamma expression in myocytes [48]. It demonstrated that the minute amount of Pparg mRNA observed in muscle extracts undergoes MCK-Cre-mediated recombination, and thus, unequivocally proved that the transcript originated in myocytes rather than other cell types that populate muscle tissue. Mice in this study developed insulin and glucose intolerance with age, and exhibited severely compromised insulin-stimulated muscle glucose uptake, as well as liver and adipose tissue IR. In contrast to the first study, here TZDs failed to ameliorate muscle insulin resistance, suggesting that myocyte PPARgamma regulates muscle insulin sensitivity cell autonomously. While the differential sensitivity of the two strains to TZDs raises concerns about the validity of the interpretations, they are not necessarily contradictory, considering that both the metabolic challenges (HFD versus aging) and the assayed activities (Insulin tolerance tests versus muscle glucose uptake) were different in each study. Still, more definitive studies, using mice with a purer genetic background and a standardized experimental approach, are required to settle these discrepancies. Regardless of the final answer, it is clear that while PPARgamma may have some metabolic functions in myocytes, these functions are not sufficiently robust to account for the systemic antidiabetic actions of TZDs.
###end p 25
###begin title 26
2.2.3. Hepatocyte-specific Pparg KO
###end title 26
###begin p 27
###xml 24 29 24 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 83 88 79 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 190 195 182 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 223 225 215 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</italic>
###xml 292 299 284 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A-Zip/F</italic>
###xml 339 344 331 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ob/ob</italic>
###xml 351 353 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B49">49</xref>
###xml 355 357 347 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B50">50</xref>
###xml 376 378 368 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</italic>
###xml 399 404 391 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 559 564 551 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 618 620 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B50">50</xref>
###xml 685 690 673 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 800 802 788 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B49">49</xref>
###xml 804 806 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B50">50</xref>
###xml 847 852 835 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ob/ob</italic>
###xml 947 952 935 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 1038 1043 1022 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 1251 1256 1231 1232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 253 258 <span type="species:ncbi:10090">mouse</span>
###xml 313 317 <span type="species:ncbi:10090">mice</span>
###xml 345 349 <span type="species:ncbi:10090">mice</span>
###xml 870 874 <span type="species:ncbi:10090">mice</span>
As in muscle, basal PPARgamma expression in liver is minimal. However, hepatic PPARgamma expression is induced substantially during steatosis. The effects of albumin Cre-mediated hepatocyte Pparg deficiency were studied in wt and two different diabetic mouse models that succumb to steatosis-A-Zip/F lipoatrophic mice and leptin-deficient ob/ob mice [49, 50]. On an otherwise wt background, hepatic Pparg deficiency caused a significant defect in TG clearance, hyperlipidemia, and increased body fat mass with age, demonstrating the importance of hepatic PPARgamma for basal fat tolerance and management of adiposity [50]. On the two diabetic backgrounds deficiency of hepatocytes for Pparg caused marked amelioration of hepatosteatosis, but exacerbated hyperlipidemia and muscle insulin resistance [49, 50]. These traits were reversed by TZDs in ob/ob, but not A-Zip/F mice, suggesting that the drugs exert their effect through activation of PPARgamma in adipocytes, not hepatocytes. Together, these studies indicate that hepatocyte PPARgamma is required for basal fat tolerance and, in addition, for steatosis of the diabetic liver, which serves to improve TG homeostasis and dampen systemic IR. However, they also clearly indicate that hepatic PPARgamma is not critical for TZD-induced insulin sensitization.
###end p 27
###begin title 28
2.2.4. Other tissue-specific Pparg KOs
###end title 28
###begin p 29
###xml 37 42 37 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 134 139 130 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
The relatively modest effects of PPARgamma deficiencies in fat, muscle, and liver provided the impetus for broadening the analysis of Pparg KO to additional cell types that participate in obesity-associated metabolic complications, namely diabetes, hypertension, and atherosclerosis. The outcomes of these analyses are briefly summarized as follows.
###end p 29
###begin p 30
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 20 24 20 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 176 180 173 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 188 190 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B51">51</xref>
Pparg deficiency in beta-islets caused a hyperplastic response without altering glucose homeostasis, ruling out a critical function of the receptor in homeostatic functions of beta cells [51].
###end p 30
###begin p 31
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B52">52</xref>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B54">54</xref>
###xml 264 269 264 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 381 386 381 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 473 478 469 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 480 482 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 484 486 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B55">55</xref>
###xml 524 529 516 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 648 653 640 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 710 712 698 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B56">56</xref>
###xml 714 716 702 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B57">57</xref>
###xml 811 816 799 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 919 921 907 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B58">58</xref>
###xml 934 939 922 923 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 619 623 <span type="species:ncbi:10090">mice</span>
###xml 822 826 <span type="species:ncbi:10090">mice</span>
A strong rationale for the generation and analysis of Pparg-null macrophages was provided by observations that TZDs induce macrophage genes that regulate lipid flux, suppress inflammatory gene expression, and ameliorate atherosclerosis [52-54]. Early studies with Pparg-null macrophages in culture and in vivo demonstrated that TZD effects on lipoprotein flux indeed depend on PPARgamma, but several of the reported anti-inflammatory effects of TZDs are independent of PPARgamma [44, 55]. Nevertheless, adaptive transfer of Pparg-deficient macrophages exacerbated genetic- and diet-induced atherosclerosis in recipient mice, demonstrating that PPARgamma performs key anti-atherogenic functions in these cells [56, 57]. In addition, a recent, yet-to-be-published symposium talk reported that macrophage-specific Pparg-null mice are glucose intolerant and exhibit increased sensitivity to HFD-induced insulin resistance [58]. Thus, PPARgamma orchestrates multiple beneficial activities in macrophages that could be harnessed for the development of advanced therapies for atherosclerosis.
###end p 31
###begin p 32
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B59">59</xref>
###xml 111 116 111 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 221 226 221 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 282 284 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B60">60</xref>
###xml 286 288 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B61">61</xref>
###xml 358 363 354 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
###xml 101 105 <span type="species:ncbi:10090">Mice</span>
Edema due to fluid retention is an undesired side effect of TZD treatment in diabetic patients [59]. Mice with Pparg KO in renal collecting duct epithelia are resistant to this TZD-borne complication, confirming that PPARgamma mediates it, apparently by enhancing sodium retention [60, 61]. This activity highlights an additional mechanism through which PPARgamma may regulate plasma volume, hypertension, and cardiovascular function.
###end p 32
###begin p 33
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 180 185 180 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 262 264 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B62">62</xref>
Pparg deletion in endothelial cells exacerbates both HFD-induced and salt-induced hypertension, and renders the condition nonresponsive to TZDs, demonstrating that endothelial PPARgamma is critical for mitigating the effects of dietary stress on blood pressure [62].
###end p 33
###begin p 34
###xml 16 21 16 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 67 72 63 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#954;</italic>
###xml 241 243 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B63">63</xref>
###xml 321 326 313 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 445 450 <span type="species:ncbi:10090">mouse</span>
Ablation of PPARgamma in cardiomyocytes causes elevated cardiac NF-kappaB activity and increased expression of cardiac embryonic genes, which lead to enhanced myofibril assembly and cardiac hypertrophy but does not affect systolic function [63]. The relationship between this phenotype and the metabolic functions of PPARgamma in other tissues is not entirely clear, although aspects of cardiac lipid metabolism have yet to be addressed in this mouse.
###end p 34
###begin title 35
2.3. Pparg2-specific KOs
###end title 35
###begin p 36
###xml 43 48 43 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 85 90 85 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 140 145 136 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 166 168 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B64">64</xref>
###xml 210 215 202 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 253 258 241 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 385 390 369 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 393 395 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B65">65</xref>
###xml 438 443 418 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 456 461 432 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 540 545 512 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 684 690 656 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg2</italic>
###xml 769 771 741 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B66">66</xref>
###xml 772 774 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B68">68</xref>
###xml 822 828 794 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg2</italic>
###xml 872 877 844 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 906 911 874 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 939 941 903 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B66">66</xref>
###xml 1236 1238 1200 1202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B66">66</xref>
###xml 1354 1362 1318 1326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lacZ-neo</italic>
###xml 1398 1404 1362 1368 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg2</italic>
###xml 1449 1455 1413 1419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg1</italic>
###xml 1457 1459 1421 1423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B67">67</xref>
###xml 1665 1667 1629 1631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B67">67</xref>
###xml 1939 1945 1903 1909 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg2</italic>
###xml 2049 2055 2013 2019 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg2</italic>
###xml 2093 2099 2057 2063 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg1</italic>
###xml 2161 2163 2125 2127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B68">68</xref>
###xml 2220 2225 2184 2185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 2238 2243 2198 2203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 2243 2250 2203 2210 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hyp/hyp</sup>
###xml 2290 2295 2250 2255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 2295 2302 2255 2262 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hyp/hyp</sup>
###xml 2449 2451 2409 2411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B68">68</xref>
###xml 2520 2526 2480 2486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg2</italic>
###xml 2558 2563 2518 2523 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 2563 2570 2523 2530 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hyp/hyp</sup>
###xml 2793 2795 2753 2755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B68">68</xref>
###xml 1877 1881 <span type="species:ncbi:10090">mice</span>
###xml 2166 2170 <span type="species:ncbi:10090">Mice</span>
Alternative promoters give rise to several Pparg isoforms with distinct 5' ends. PPARgamma1 is the ubiquitous isoform, expressed in all PPARgamma-expressing tissues [64]. Adipocytes express, in addition to PPARgamma1, a cell-specific isoform termed PPARgamma2, whose unique 5' exon encodes a 30 residue-long N-terminal extension of the ligand-independent transactivation domain of PPARgamma1 [65]. Because the placenta expresses only PPARgamma1, KO of PPARgamma2 could provide yet another means to bypass the lethal outcome of constitutive Pparg deficiency, as well as to interrogate potential unique functions of this adipocyte-specific isoform. In all, three teams have knocked out Pparg2 using distinct targeting strategies that produced slightly different results [66-68]. Knock-in of red fluorescent protein into the Pparg2-specific B exon produced a clean KO of PPARgamma2 while retaining normal PPARgamma1 expression in adipocytes [66]. This configuration interfered with adipocyte differentiation in vitro and markedly reduced fat mass in vivo. This lipodystrophic phenotype involved significant reduction in the size, number, and TG content of brown and white adipocytes, and decreased expression of typical adipocyte markers [66]. A second knockout configuration entailed replacement of the entire B exon and flanking intronic sequences with a lacZ-neo cassette and resulted in a similar Pparg2-specific gene disruption, without affecting Pparg1 [67]. This configuration was as detrimental to adipocyte differentiation in vitro as the previous KO configuration, but unlike that KO it had only a marginal effect on either fat mass or basal adipocyte size [67]. It is unclear whether these differences are meaningful or rather reflect minor differences in the experimental setup used by the two teams, for example in allele configuration, the genetic background of the mice, composition of the chow, or analytical methods. A third Pparg2 targeting configuration, which resulted from an intronic neo cassette downstream of exon B, eliminated Pparg2 expression but inadvertently altered Pparg1 expression, abolishing it in WAT while augmenting it in BAT [68]. Mice homozygous for this modification were deemed PPARgamma hypomorphs (Pparghyp/hyp). Unlike the first two configurations, Pparghyp/hyp were subject to high mortality rate and growth retardation during infancy; survivors thrived after weaning but were substantially lipodystrophic [68]. Importantly, contrary to other models of lipodystrophy, all three Pparg2-null configurations, including Pparghyp/hyp, exhibited a surprisingly modest decrease in glucose or insulin tolerance and did not develop steatosis. The suggestion that this relatively healthy phenotype is mitigated by compensatory lipid oxidation in muscle tissue [68] has to be reconciled with the failure of a similar compensatory mechanism to offset other cases of lipodystrophy.
###end p 36
###begin title 37
###xml 50 55 <span type="species:ncbi:9606">human</span>
###xml 56 64 <span type="species:ncbi:9606">patients</span>
2.4. Knock-in of dominant-negative mutations from human patients
###end title 37
###begin p 38
###xml 120 131 120 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg-L466A</italic>
###xml 135 146 135 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg-P465L</italic>
###xml 312 314 312 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</italic>
###xml 481 483 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B69">69</xref>
###xml 484 486 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B73">73</xref>
###xml 542 547 542 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 733 735 733 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B74">74</xref>
###xml 737 739 737 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B75">75</xref>
###xml 1073 1075 1073 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B74">74</xref>
###xml 1077 1079 1077 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B75">75</xref>
###xml 1092 1097 1092 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 1097 1104 1097 1104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P465L/+</italic>
###xml 1097 1104 1097 1104 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>P465L/+</italic></sup>
###xml 1201 1203 1201 1203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</italic>
###xml 1261 1266 1261 1266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 1291 1293 1291 1293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B74">74</xref>
###xml 1365 1370 1365 1370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 1370 1377 1370 1377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">L466A/+</italic>
###xml 1370 1377 1370 1377 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>L466A/+</italic></sup>
###xml 1395 1400 1395 1400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 1400 1407 1400 1407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P465L/+</italic>
###xml 1400 1407 1400 1407 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>P465L/+</italic></sup>
###xml 1503 1505 1503 1505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B75">75</xref>
###xml 98 102 <span type="species:ncbi:10090">mice</span>
###xml 202 207 <span type="species:ncbi:9606">human</span>
###xml 245 253 <span type="species:ncbi:9606">Patients</span>
###xml 536 541 <span type="species:ncbi:10090">mouse</span>
###xml 742 746 <span type="species:ncbi:10090">Mice</span>
###xml 854 858 <span type="species:ncbi:10090">mice</span>
###xml 1063 1071 <span type="species:ncbi:9606">patients</span>
###xml 1105 1109 <span type="species:ncbi:10090">mice</span>
###xml 1204 1208 <span type="species:ncbi:10090">mice</span>
###xml 1285 1289 <span type="species:ncbi:10090">mice</span>
###xml 1378 1382 <span type="species:ncbi:10090">mice</span>
###xml 1408 1412 <span type="species:ncbi:10090">mice</span>
###xml 1556 1561 <span type="species:ncbi:9606">human</span>
As if the analyses described to this point were not sufficiently counterintuitive and indecisive, mice heterozygous for Pparg-L466A or Pparg-P465L-two dominant-negative missense mutations identified in human subjects-provided further surprises. Patients carrying one allele of either mutation alongside a second wt allele suffer from partial congenital lipodystrophy with hallmarks of the metabolic syndrome, including dyslipidemia, early-onset type II diabetes, and hypertension [69-73]. It therefore made perfect sense to replace the mouse Pparg gene with similar mutations, with the obvious expectation of recapitulating the clinical phenotype. Two research teams carried out this endeavor, each knocking in one of the mutations [74, 75]. Mice homozygous for either mutation died in utero, demonstrating the null nature of the alleles. However, while mice heterozygous for either mutation exhibited moderate hypertension and anomalies of either fat distribution or adipocyte morphology, none fully recapitulated the lipodystrophic phenotype of the orthologous patients [74, 75]. Moreover, PpargP465L/+ mice displayed no gross changes in plasma chemistry and were in fact more glucose tolerant than wt mice, both basally and following HFD, just like standard Pparg-haploinsufficient mice [74]. In addition, although more physiological anomalies were reported for PpargL466A/+ mice compared to PpargP465L/+ mice, including elevated free FA levels, hepatic steatosis and HFD-induced insulin resistance [75], their morbidity did not amount to that of their human counterparts.
###end p 38
###begin title 39
2.5. Other genetic manipulations of Pparg
###end title 39
###begin p 40
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B76">76</xref>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B79">79</xref>
###xml 568 573 568 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 575 577 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B80">80</xref>
###xml 580 585 576 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 585 596 581 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S112A/S112A</italic>
###xml 585 596 581 592 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>S112A/S112A</italic></sup>
###xml 730 735 726 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 848 850 840 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B80">80</xref>
###xml 976 981 968 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 1219 1224 1207 1208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 321 326 <span type="species:ncbi:9606">human</span>
###xml 597 601 <span type="species:ncbi:10090">mice</span>
###xml 777 781 <span type="species:ncbi:10090">mice</span>
###xml 1251 1255 <span type="species:ncbi:10090">mice</span>
In addition to the Pparg KO onslaught, there has been a substantial public health interest in more subtle aspects of its function. These include the effects of genetic polymorphisms and post-translational modifications, which have been linked both genetically and epidemiologically to obesity and type II diabetes in the human population [76-79]. The first reported effort that undertook this approach is the S112A point mutation, which eliminates a MAP kinase phosphorylation site that inhibits the transcriptional activation capacity and adipogenic functions of PPARgamma [80]. PpargS112A/S112A mice are viable and healthy, and do not display physiological anomalies under normal husbandry. However, the failure to regulate PPARgamma action by phosphorylation protects these mice against HFD-induced adipocyte hypertrophy and insulin resistance [80]. These results validate the utility of subtle structural mutations for uncovering important physiological activities of PPARgamma. Informal communications with other researchers, as well as the public NIH grant database, reveal that additional genetic manipulations aimed at understanding the biological function of conserved and polymorphic sequence elements of PPARgamma are currently underway in mice.
###end p 40
###begin title 41
2.6. Pparg KOs-summary and remarks
###end title 41
###begin p 42
###xml 102 107 102 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 239 244 235 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 263 268 259 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 364 369 360 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 555 560 551 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 729 734 721 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 802 807 794 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 1271 1276 1259 1264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 1420 1422 1408 1410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 1424 1426 1412 1414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 1485 1497 1473 1481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947; per se</italic>
###xml 1782 1787 1766 1767 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 2749 2751 2729 2731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B72">72</xref>
###xml 2843 2848 2823 2828 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 2907 2912 2887 2888 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 3181 3186 3157 3158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 383 388 <span type="species:ncbi:9606">human</span>
###xml 389 397 <span type="species:ncbi:9606">patients</span>
###xml 431 436 <span type="species:ncbi:10090">mouse</span>
###xml 468 473 <span type="species:ncbi:10090">mouse</span>
###xml 1284 1289 <span type="species:ncbi:10090">mouse</span>
###xml 1293 1298 <span type="species:ncbi:9606">human</span>
###xml 1403 1407 <span type="species:ncbi:10090">mice</span>
###xml 1412 1418 <span type="species:ncbi:9606">humans</span>
###xml 1680 1684 <span type="species:ncbi:10090">mice</span>
###xml 1757 1763 <span type="species:ncbi:9606">humans</span>
###xml 1909 1913 <span type="species:ncbi:10090">mice</span>
###xml 2029 2034 <span type="species:ncbi:9606">human</span>
###xml 2481 2486 <span type="species:ncbi:9606">human</span>
###xml 2564 2570 <span type="species:ncbi:9606">person</span>
###xml 2733 2738 <span type="species:ncbi:9606">human</span>
###xml 2863 2867 <span type="species:ncbi:10090">mice</span>
###xml 3307 3311 <span type="species:ncbi:10090">mice</span>
###xml 3316 3319 <span type="species:ncbi:9606">men</span>
In aggregate, a slew of attempts to generate molecular genetic models that will reveal a role for PPARgamma in obesity, insulin resistance, and related metabolic disorders have yielded partial success and confounding results. Constitutive Pparg KO was nonviable, Pparg haploinsufficiency was unexpectedly beneficial, and the pathogenic effect of dominant-negative Pparg mutations in human patients was not faithfully replicated in mouse models. Reassuringly, chimeric mouse studies and adipocyte-specific KOs unequivocally proved the critical role of PPARgamma in adipocyte differentiation and survival. However, the potential for an interpretable effect on energy metabolism was thwarted by the inability to obtain long-lasting Pparg-null adipocytes, which did not allow teasing out the effect of PPARgamma deficiency from the general impact of lipodystrophy. Quite disappointingly, KOs in other tissues had relatively modest effects basally and latent metabolic defects in response to dietary or genetic challenges. While these studies invoked encouraging links to atherosclerosis and hypertension, none amounted to full-blown IR, let alone diabetes. These major deviations from straightforward expectations raise concerns about the applicability of genetic studies of Pparg in the mouse to human metabolism. However, one should be reminded that TZDs are equally potent as insulin sensitizers in both mice and humans [35, 36], highly suggestive of similar metabolic functions of PPARgamma per se across species. A more likely explanation for the relatively benign outcomes of these studies is the inherently fickle nature of genetic, physiological, and metabolic experiments in mice. Evolution likely differentiated metabolic physiology in rodents versus humans, and although PPARgamma may have the exact same function in the bigger scheme, other genes and pathways may modify the outcome. In addition, lab mice are reared in a highly controlled ambient and provided either with uniform lean chow that differs drastically from human diet, or with experimental diets that mimic our own dietary follies, but which rodents have not evolved to handle. Effects of genetic background and modifier genes on outcomes and their interpretation comprise another obstacle. On the one hand, many of the studies summarized here do not clarify the extent of genetic homogeneity of the tested cohorts, potentially obstructing minor, yet critical effects of the mutations. On the other hand, the human population is genetically diverse, and gene defects that would devastate one person could be inconsequential in another. A case in point is the dramatic exacerbating effect of a mutation in the PPP1R3A gene on the outcome of PPARG mutations in a human pedigree [72]. Genes and pathways with comparable modifying effects could compensate for the effects of Pparg deficiency in mice. Moreover, redundant activities of PPARgamma in different tissues or an altogether misguided choice of target tissues and readouts might have further hindered interpretation. Finally, it may be time to start entertaining the notion that the problem might be with the hypothesis itself: clearly, activation of PPARgamma with TZDs is a robust therapy for IR, but does this mean that the pathway is necessary for basal insulin sensitivity in mice and men?
###end p 42
###begin title 43
###xml 7 12 7 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
3. PPARdelta
###end title 43
###begin p 44
###xml 4 9 4 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 173 175 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B64">64</xref>
###xml 241 246 237 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 349 354 341 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 435 440 423 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 464 469 452 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 742 747 730 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 446 450 <span type="species:ncbi:10090">mice</span>
PPARdelta was initially regarded as a promising prospect for studies of obesity and associated diseases purely on the merit of its pharmaceutically accomplished homologues [64]. With pharmacological agonists and genetic manipulations of PPARdelta coming to fruition in recent years, these expectations are starting to be realized, and implicate PPARdelta in important aspects of obesity, energy metabolism and metabolic disease. As in Pparg-null mice, analysis of Ppard deficiency also faces the challenge of substantial embryonic mortality, albeit for completely different reasons. The nature of the challenge, the different solutions, and the associated caveats are discussed briefly as a primer to the review of phenotypes associated with Ppard-null and gain-of-function models.
###end p 44
###begin p 45
###xml 10 15 10 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 144 149 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 259 261 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B81">81</xref>
###xml 262 264 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B83">83</xref>
###xml 442 444 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B81">81</xref>
###xml 515 520 511 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 535 537 531 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</italic>
###xml 882 887 878 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 1014 1019 1010 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 1153 1155 1149 1151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</italic>
###xml 1178 1183 1174 1179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 1246 1248 1242 1244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B84">84</xref>
###xml 1275 1280 1271 1276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 1520 1525 1516 1517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 1699 1704 1691 1692 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 1722 1727 1710 1715 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 1765 1767 1753 1755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B81">81</xref>
###xml 1769 1771 1757 1759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B85">85</xref>
###xml 1819 1824 1807 1812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 1970 1975 1958 1963 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 2135 2140 2123 2128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 59 63 <span type="species:ncbi:10090">mice</span>
###xml 526 530 <span type="species:ncbi:10090">mice</span>
###xml 794 798 <span type="species:ncbi:10090">mice</span>
###xml 1025 1029 <span type="species:ncbi:10090">mice</span>
###xml 1566 1570 <span type="species:ncbi:10090">mice</span>
###xml 1981 1985 <span type="species:ncbi:10090">mice</span>
In all, 6 Ppard-null configurations have been generated in mice. Three knockout strains harboring deletions or insertions that wipe out the PPARdelta protein product in its entirety cause severe placental defects that lead to substantial embryonic mortality [81-83]. While there are practically no surviving homozygous null animals on the standard, C57BL/6 (B6) background, survival is increased to between 5% and 20% on outbred B6 : 129/Sv [81] or FVB : B6 backgrounds (Y. Barak, unpublished data). Unfortunately, Ppard-null mice and wt controls generated in this fashion inherently possess mixed genetic backgrounds, whose stochastic quantitative trait locus effects significantly muddle physiological data. In addition, through successive interbreeding of surviving homozygous null FVB : B6 mice over several generations, our lab has managed to generate a genetically semistable Ppard-null stock with approximately 50% survival (Y. Barak, unpublished data). However, while this stock provides a higher yield of Ppard-null mice with a relatively isogenic background, the nature of the breeding strategy hindered the generation of genetically matching wt controls. In a fourth Ppard null allele, no substantial embryonic lethality was reported [84]. However, in this allele Ppard was truncated 60 amino acids from its C-terminus, leaving its entire DNA-binding domain and most of its ligand-binding domain intact, and raising a reasonable concern that it is a hypomorph that enabled embryonic survival via residual PPARdelta functions. Therefore, analyses of adult mice carrying this KO configuration have to be interpreted with the cautionary note that it is likely incompletely deficient for PPARdelta. Finally, floxed Ppard alleles have been generated as well [81, 85]. These configurations enable the targeting of Ppard in specific tissues with the obvious caveat that Cre-mediated deletion of floxed alleles is seldom fully penetrant. To avoid confusion, the term Ppard-null mice is used in the following text to describe animals with germ-line deletion of the gene in all tissues, whereas studies performed with tissue-specific Ppard KOs are spelled out.
###end p 45
###begin title 46
###xml 34 39 34 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
3.1. Genetic manipulations of PPARdelta and adipose tissue
###end title 46
###begin p 47
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B81">81</xref>
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B84">84</xref>
###xml 193 198 193 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 217 234 217 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard x Fabp4-Cre</italic>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B81">81</xref>
###xml 335 340 335 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 436 441 432 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 549 551 545 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</italic>
###xml 562 564 558 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B86">86</xref>
###xml 566 568 562 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B87">87</xref>
###xml 677 682 673 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 702 704 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B87">87</xref>
###xml 726 731 718 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fabp4</italic>
###xml 874 879 866 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 881 895 869 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fabp4-VP-Ppard</italic>
###xml 1025 1039 1013 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fabp4-VP-Ppard</italic>
###xml 1206 1208 1194 1196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B87">87</xref>
###xml 1380 1382 1368 1370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B87">87</xref>
###xml 1628 1633 1616 1617 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 1642 1644 1626 1628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B87">87</xref>
###xml 1683 1688 1667 1668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 1769 1773 1749 1753 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ucp1</italic>
###xml 1783 1785 1763 1765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B87">87</xref>
###xml 1883 1888 1863 1864 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 36 40 <span type="species:ncbi:10090">mice</span>
###xml 204 208 <span type="species:ncbi:10090">mice</span>
###xml 447 451 <span type="species:ncbi:10090">mice</span>
###xml 635 639 <span type="species:ncbi:10090">mice</span>
###xml 716 720 <span type="species:ncbi:10090">mice</span>
###xml 1040 1044 <span type="species:ncbi:10090">mice</span>
###xml 1224 1228 <span type="species:ncbi:10090">mice</span>
###xml 1414 1418 <span type="species:ncbi:10090">mice</span>
Early studies of outbred Ppard-null mice under standard husbandry conditions revealed a substantial decrease in the size of BAT and WAT [81, 84]. Fat mass was not reduced in adipocyte-specific Ppard-null mice (floxed Ppard x Fabp4-Cre) [81], demonstrating that this trait is not adipocyte-autonomous, and must result from impaired PPARdelta activity in other tissues. While unable to achieve normal adiposity on standard, low fat chow, Ppard-null mice underwent a quicker and substantially more aggressive weight gain in response to HFD compared to wt controls [86, 87]. These observations were complemented and extended by studies of mice expressing constitutively active PPARdelta in adipose tissue [87]. In these mice, the Fabp4 promoter drives adipocyte-specific expression of a fusion protein between the transactivation domain of the Herpes Virus VP16 protein and PPARdelta (Fabp4-VP-Ppard), such that the latter is rendered permanently active, irrespective of endogenous ligands. When reared on standard, low-fat chow Fabp4-VP-Ppard mice exhibited significant reduction in body weight and in the overall mass and TG content of adipose tissue, as well as in the levels of circulating TG and free FA [87]. However, the mice were protected from the adipocyte hypertrophy, dyslipidemia, obesity, and steatosis that occur in response to either HFD or impaired leptin signaling [87]. Quelling of obesity in these mice was associated with upregulation of genes that control lipid catabolism and adaptive thermogenesis in both BAT and WAT; reassuringly, the same genes are induced in response to systemic administration of a PPARdelta ligand [87]. In contrast, adipocyte-specific PPARdelta deficiency compromised HFD-mediated induction of the uncoupling protein 1 gene, Ucp1, in BAT [87]. Combined, these two genetic extremes of deficiency versus constitutive activation identify PPARdelta as a critical regulator of lipid homeostasis and adiposity.
###end p 47
###begin title 48
###xml 34 39 34 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
3.2. Genetic manipulations of PPARdelta and muscle
###end title 48
###begin p 49
###xml 31 36 31 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 96 97 92 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 145 150 141 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 193 198 185 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 269 274 261 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 368 376 356 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VP-Ppard</italic>
###xml 544 546 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B88">88</xref>
###xml 781 783 769 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B88">88</xref>
###xml 804 812 792 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt Ppard</italic>
###xml 927 929 915 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B89">89</xref>
###xml 1026 1028 1014 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</italic>
###xml 1033 1038 1021 1022 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 1152 1157 1136 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 1247 1249 1231 1233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B85">85</xref>
###xml 1303 1308 1287 1288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 1370 1375 1350 1351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 1509 1514 1485 1486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 1535 1537 1507 1509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B85">85</xref>
###xml 1581 1586 1553 1554 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 1714 1719 1682 1683 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 1789 1791 1753 1755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B88">88</xref>
###xml 1849 1854 1813 1818 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 1934 1936 1898 1900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B85">85</xref>
###xml 2016 2021 1980 1985 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 2118 2120 2082 2084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B90">90</xref>
###xml 2205 2210 2169 2170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 981 986 <span type="species:ncbi:10090">mouse</span>
###xml 1280 1284 <span type="species:ncbi:10090">mice</span>
###xml 1611 1615 <span type="species:ncbi:10090">mice</span>
###xml 2027 2031 <span type="species:ncbi:10090">mice</span>
The abundant expression of PPARdelta in myocytes suggests an important role in skeletal muscle [2]. Two transgenic models of muscle-specific PPARdelta overexpression and one of muscle-specific Ppard-deficiency confirmed this notion and revealed a massive impact of PPARdelta on muscle and whole body physiology. MCK promoter-driven expression of constitutively active VP-Ppard resulted in a dramatic type switch of muscle from type II, glycolytic fibers to type I, slow-twitch, oxidative fibers, and a staggering increase in aerobic endurance [88]. This switch was associated with activation of the typical oxidative fiber expression program, including genes that regulate lipid catabolism, mitochondrial electron transfer, oxidative metabolism, and type I contractile structures [88]. Overexpression of wt Ppard in skeletal muscle activates a similar expression pattern, and falls just short of inducing fiber-type switching [89]; the tamer induction of these genes in the latter mouse strain reflects the lesser activity of wt PPARdelta compared to the VP16-fused variant. These observations were fully corroborated by skeletal muscle-specific KO of Ppard, which resulted in the reciprocal muscle type switch from high- to low-oxidative fibers [85]. Molecular analyses of these mice revealed that PPARdelta regulates the expression of the transcriptional cofactor PGC1alpha, which regulates mitochondrial biogenesis and muscle type switch, providing a plausible mechanistic explanation for the basis of PPARdelta function in muscle [85]. Remarkably, constitutive activity of PPARdelta in muscle protected the mice from HFD-induced adipocyte hypertrophy, obesity, and IR, demonstrating the major influence of PPARdelta-induced energy dissipation in muscle on systemic energy homeostasis [88]. In full agreement with these findings, muscle-specific Ppard deficiency resulted in obesity, adipocyte hypertrophy, and insulin resistance [85]. Moreover, the basal respiratory quotient and glucose tolerance of whole-body Ppard-null mice are significantly reduced in the absence of additional dietary or genetic challenges [90]. Combined, these observations indicate that enhancement of basal metabolism by PPARdelta in general, and in muscle in particular, are critical for systemic energy homeostasis, and play a pivotal role in curbing obesity and its metabolic sequelae.
###end p 49
###begin p 50
###xml 138 143 138 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 191 196 187 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 215 230 211 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard x MHC-Cre</italic>
###xml 399 401 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B91">91</xref>
###xml 553 558 549 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 601 603 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B91">91</xref>
###xml 647 652 639 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 702 704 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B81">81</xref>
###xml 706 708 698 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B85">85</xref>
###xml 821 826 813 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 999 1004 987 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 202 206 <span type="species:ncbi:10090">mice</span>
###xml 408 412 <span type="species:ncbi:10090">mice</span>
###xml 623 627 <span type="species:ncbi:10090">mice</span>
###xml 736 740 <span type="species:ncbi:10090">mice</span>
In addition to the gain and loss-of-function studies in skeletal muscle, loss-of-function studies revealed a critical requirement for PPARdelta also in cardiac muscle. Cardiomyocyte-specific Ppard-null mice (floxed Ppard x MHC-Cre) exhibited reduced expression of genes regulating FA oxidation, accompanied by progressive cardiac lipid accumulation, cardiac hypertrophy, and dilated cardiomyopathy [91]. The mice develop typical symptoms of congestive heart failure and died within the first 10 months of life, demonstrating the vital importance of PPARdelta for myocardial FA oxidation and function [91]. Considering that mice carrying germ-line Ppard deficiency reach old age without major incident [81, 85], the harsher phenotype of mice that lack this PPAR only in the heart requires explanation. In addition, as PPARalpha induces similar pathways of cardiac FA oxidation and protection from lipotoxicity (see above), it will be crucial to determine how these differ from those regulated by PPARdelta, and why neither PPAR compensates for the deficiency of the other.
###end p 50
###begin title 51
###xml 34 39 34 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
3.3. Genetic manipulations of PPARdelta and atherosclerosis
###end title 51
###begin p 52
###xml 31 36 31 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 176 178 172 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</italic>
###xml 186 191 182 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 308 313 304 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 409 414 401 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 428 430 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B82">82</xref>
###xml 549 554 537 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 566 568 554 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B86">86</xref>
###xml 618 623 606 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 771 776 755 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 851 856 831 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 916 918 892 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B92">92</xref>
###xml 950 955 926 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 1052 1057 1028 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 1068 1070 1040 1042 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B92">92</xref>
###xml 1100 1105 1072 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 1195 1200 1163 1164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 1446 1451 1410 1415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 1530 1532 1494 1496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B92">92</xref>
###xml 1551 1556 1515 1516 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 1635 1640 1595 1596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 560 564 <span type="species:ncbi:10090">mice</span>
###xml 1524 1528 <span type="species:ncbi:10090">mice</span>
The abundant expression of PPARdelta in macrophages provided a compelling rationale to study its contribution to macrophage biology and atherosclerosis. Comparative studies of wt versus Ppard-null embryonic stem cell-derived macrophages identified very low-density lipoprotein (VLDL) as a rich source of PPARdelta agonists and the gene for the lipid droplet-associated ADRP protein as a tightly regulated PPARdelta target gene [82]. Combined with the observed increases in hepatic VLDL production, circulating VLDL levels, and VLDL-associated TG in Ppard-null mice [86], this functional interaction suggested that PPARdelta is engaged in negative feedback regulation of systemic VLDL flux. While these studies provide circumstantial support for the potential role of PPARdelta in macrophage lipid metabolism, subsequent studies found no effect of PPARdelta deletion or activation on cholesterol flux in macrophages [92]. In contrast, deletion of the Ppard gene reduced the expression of pro-inflammatory genes in macrophages, as did treatment with PPARdelta agonists [92]. The similar effects of PPARdelta deficiency and activation invoke a mechanism, in which the association of unliganded PPARdelta with transcriptional corepressors promotes inflammation, which can be relieved by either ligand-mediated derepression or an outright gene KO. Most importantly, these activities have a measurable impact on atherosclerosis, and transplantation of Ppard-null bone marrow markedly suppressed atherosclerosis in LDL-receptor KO mice [92]. Thus, basal PPARdelta activity in macrophages augments the pathogenesis of atherosclerosis, and PPARdelta ligands may exert therapeutic effects by reversing, rather than enhancing, this pathogenic activity.
###end p 52
###begin title 53
4. SUMMARY AND PROSPECTS
###end title 53
###begin p 54
###xml 138 142 <span type="species:ncbi:10090">mice</span>
This review summarized the insights obtained into the functions of PPARs in obesity and metabolic disease through genetic manipulation of mice. For focus purposes, we excluded many of the studies that provided seminal insights into the in vivo functions of PPARs through the use of pharmacological agents; this information is available in other reviews in this volume and elsewhere.
###end p 54
###begin p 55
###xml 91 96 91 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 102 107 98 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 117 122 109 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 353 361 341 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
It is evident from the studies reviewed that deficiencies or unscheduled expression of PPARalpha, PPARgamma, and PPARdelta impact multiple tissues and vital metabolic processes, and that despite their substantial homology and evidence of shared transcriptional targets, the physiological functions of each are unique. These observations are compiled in Figure 1.
###end p 55
###begin p 56
###xml 120 125 120 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 179 184 175 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 255 260 247 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 462 467 450 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
Some of the conclusions that emerge from these studies are consistent and irrefutable, such as the critical role of PPARalpha in the fasting response, the indispensability of PPARgamma for adipocyte differentiation and survival, or the role of muscle PPARdelta in fiber type determination and basal oxidative metabolism. Other conclusions are solid, but could be refined and extended by further studies; examples include the antiatherosclerotic functions of PPARgamma. However, many studies report data and conclusions that seem either overstated or in conflict altogether with other studies. Nevertheless, in case of studies in the latter category we tried our best to summarize the data as published, point out major discrepancies, and where possible, provide plausible explanations for disparities between reports, while leaving it to the readers to formulate their own judgment. Still, the text is likely permeated with some of our own biases, formed through informal discussions with other researchers, familiarity with the evolution of some of the concepts and hypotheses, and our own unpublished work.
###end p 56
###begin p 57
###xml 296 301 <span type="species:ncbi:9606">human</span>
As pointed out throughout this review, inconsistencies or erroneous data could readily arise from minor imperfections in the targeting strategy, inappropriate heterogeneity of the genetic background, differences in husbandry, feeding regimens and experimental protocols, and, last but not least, human error. Although these issues need to be ironed out in the long term, one may take the philosophical stance that hard-to-reproduce results are too minor to be biologically significant. This leaves us with the larger, yet-to-be-answered questions that should be addressed by genetic manipulations of PPARs in the near future.
###end p 57
###begin p 58
###xml 54 59 54 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 212 217 208 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 417 422 409 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppara</italic>
Currently one of the biggest questions concerning PPARalpha is the therapeutic promise of fibrate drugs and derivatives, which have been all but neglected in recent years. Considering the unique functions of PPARalpha in lipid clearance and the fasting response, are there adverse metabolic conditions for which the potential of its agonists to provide an ideal treatment has been overlooked? The combined effects of Ppara KO and agonists on animal models of various diseases that entail altered lipid homeostasis should provide answers to this question.
###end p 58
###begin p 59
###xml 8 13 8 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 368 373 364 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 477 482 469 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 520 525 512 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 637 642 629 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 764 769 756 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 960 965 948 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 1040 1045 1024 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 1162 1167 1146 1151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pparg</italic>
###xml 620 624 <span type="species:ncbi:10090">mice</span>
For PPARgamma, several mysteries beg resolution, none more important than its connection to insulin sensitization, which has thus far eluded definitive proof. The following are three examples for the many potential approaches that could be employed to address this topical issue. First, beyond its importance for adipogenesis and adipocyte viability, is adipocyte PPARgamma a major player in systemic metabolism? Can we gain a molecular understanding of the death mechanism of Pparg-null adipocytes and use it to delete Pparg in these cells while averting their death? Assuming that we can devise such methods to obtain mice with viable Pparg-null adipocytes, what would their metabolic phenotype be? Second, we should continue to explore the contributions of PPARgamma to metabolic homeostasis through its actions in additional tissues. Considering the critical role of central regulation in energy homeostasis, one glaringly neglected hypothesis is that PPARgamma may also function centrally; this idea could be tested by tissue-specific Pparg KOs in the CNS and hypothalamic neurons. Third, we do not yet understand the mechanisms of insulin sensitization by Pparg haploinsufficiency. Additional in vivo experiments are required to identify the culprit tissue(s) and the target genes whose deregulation underlies this phenomenon.
###end p 59
###begin p 60
###xml 4 9 4 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 55 60 51 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 69 74 61 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 147 152 135 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 255 260 243 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 340 345 324 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ppard</italic>
###xml 351 355 <span type="species:ncbi:10090">mice</span>
PPARdelta research has been lagging behind that of PPARalpha and PPARgamma, and new findings are starting to trickle from multiple tissue-specific Ppard KOs. The immediate significant questions revolve around the detailed mechanistic understanding of PPARdelta action in lipid and oxidative metabolism and in inflammation. Considering that Ppard-null mice surviving gestation are by and large healthy under standard husbandry, how important are these functions for basal health? And when these functions come into play under metabolic stress, how can they be modulated for the best possible treatment of metabolic diseases? As pointed out above, combination studies of pharmacological agonists and genetically manipulated animals will bring us several steps closer to answering these questions.
###end p 60
###begin title 61
ACKNOWLEDGMENTS
###end title 61
###begin p 62
The authors wish to thank Stephen Sampson for critical reading and comments on the manuscript, Jesse Hammer for expert graphics, and Pat Cherry for administrative assistance. Y. B. is supported in part by NIH Grant HD044103 and by a grant from The March of Dimes. S. K. is a recipient of an AHA Northeast Affiliate Postdoctoral Fellowship.
###end p 62
###begin article-title 63
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
###end article-title 63
###begin article-title 64
###xml 108 113 108 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 116 120 112 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 127 132 120 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 146 149 <span type="species:ncbi:10116">rat</span>
Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat
###end article-title 64
###begin article-title 65
###xml 27 32 27 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators
###end article-title 65
###begin article-title 66
###xml 130 135 130 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 141 146 137 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 70 74 <span type="species:ncbi:10090">mice</span>
Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha)
###end article-title 66
###begin article-title 67
###xml 84 89 84 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 100 104 <span type="species:ncbi:10090">mice</span>
Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice
###end article-title 67
###begin article-title 68
###xml 43 48 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis
###end article-title 68
###begin article-title 69
###xml 43 48 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 118 123 114 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#954;</italic>
Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging
###end article-title 69
###begin article-title 70
###xml 43 48 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 136 141 <span type="species:ncbi:10090">mouse</span>
Peroxisome proliferator-activated receptor-alpha regulates lipid homeostasis, but is not associated with obesity. Studies with congenic mouse lines
###end article-title 70
###begin article-title 71
###xml 4 9 4 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
PPARalpha is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue
###end article-title 71
###begin article-title 72
###xml 67 72 67 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 78 83 74 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 127 132 119 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 138 143 <span type="species:ncbi:10090">mouse</span>
A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders
###end article-title 72
###begin article-title 73
###xml 43 48 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting
###end article-title 73
###begin article-title 74
###xml 43 48 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 54 59 50 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
Peroxisome-proliferator-activated receptor-alpha (PPARalpha) deficiency leads to dysregulation of hepatic lipid and carbohydrate metabolism by fatty acids and insulin
###end article-title 74
###begin article-title 75
###xml 19 24 19 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
Requirement of PPARalpha in maintaining phospholipid and triacylglycerol homeostasis during energy deprivation
###end article-title 75
###begin article-title 76
###xml 43 48 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 54 59 50 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
Peroxisome proliferator-activated receptor alpha (PPARalpha) influences substrate utilization for hepatic glucose production
###end article-title 76
###begin article-title 77
###xml 8 15 8 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 72 77 72 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 88 92 <span type="species:ncbi:10090">mice</span>
Hepatic de novo synthesis of glucose-6-phosphate is not affected in PPARalpha-deficient mice but is preferentially directed towards hepatic glycogen stores after a short-term fast
###end article-title 77
###begin article-title 78
Nuclear receptor signaling and cardiac energetics
###end article-title 78
###begin article-title 79
###xml 108 113 108 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity
###end article-title 79
###begin article-title 80
###xml 114 119 114 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor alpha-deficient mice
###end article-title 80
###begin article-title 81
###xml 37 42 37 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus
###end article-title 81
###begin article-title 82
###xml 5 10 5 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 16 20 <span type="species:ncbi:10090">mice</span>
PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance
###end article-title 82
###begin article-title 83
###xml 61 66 61 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 98 102 <span type="species:ncbi:10090">mice</span>
Dexamethasone induction of hypertension and diabetes is PPAR-alpha dependent in LDL receptor-null mice
###end article-title 83
###begin article-title 84
###xml 43 48 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
Peroxisome proliferator-activated receptor alpha mediates the effects of high-fat diet on hepatic gene expression
###end article-title 84
###begin article-title 85
###xml 43 48 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 98 102 <span type="species:ncbi:10090">mice</span>
Peroxisome proliferator-activated receptor-alpha deficiency does not alter insulin sensitivity in mice maintained on regular or high-fat diet: hyperinsulinemic-euglycemic clamp studies
###end article-title 85
###begin article-title 86
###xml 18 23 18 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 143 148 <span type="species:ncbi:10090">mouse</span>
Deficiency of PPARalpha disturbs the response of lipogenic flux and of lipogenic and cholesterogenic gene expression to dietary cholesterol in mouse white adipose tissue
###end article-title 86
###begin article-title 87
###xml 136 141 136 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 202 207 198 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knock-out mice. Evidence for compensatory regulation by PPARdelta
###end article-title 87
###begin article-title 88
###xml 75 80 75 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
A potential link between muscle peroxisome proliferator-activated receptor-alpha signaling and obesity-related diabetes
###end article-title 88
###begin article-title 89
###xml 43 48 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 54 58 <span type="species:ncbi:10090">mice</span>
Peroxisome proliferator-activated receptor-alpha-null mice have increased white adipose tissue glucose utilization, GLUT4, and fat mass: role in liver and brain
###end article-title 89
###begin article-title 90
###xml 107 112 107 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 118 123 114 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARgamma)
###end article-title 90
###begin article-title 91
###xml 14 16 10 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sup>
###xml 17 19 13 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 34 35 30 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">J</italic>
###xml 35 36 31 32 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 92 97 88 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
15-Deoxy-Delta12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARgamma
###end article-title 91
###begin article-title 92
###xml 50 55 50 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
Stimulation of adipogenesis in fibroblasts by PPARgamma2, a lipid-activated transcription factor
###end article-title 92
###begin article-title 93
###xml 4 9 4 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
PPARgamma is required for placental, cardiac, and adipose tissue development
###end article-title 93
###begin article-title 94
###xml 4 9 4 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
PPARgamma is required for the differentiation of adipose tissue in vivo and in vitro
###end article-title 94
###begin article-title 95
###xml 60 65 60 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle
###end article-title 95
###begin article-title 96
###xml 43 48 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 124 129 <span type="species:ncbi:10090">mouse</span>
Peroxisome proliferator-activated receptor gamma is required in mature white and brown adipocytes for their survival in the mouse
###end article-title 96
###begin article-title 97
###xml 4 9 4 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
PPARgamma and the treatment of insulin resistance
###end article-title 97
###begin article-title 98
The potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosis
###end article-title 98
###begin article-title 99
###xml 43 47 <span type="species:ncbi:10090">mice</span>
Epiblast-restricted Cre expression in MORE mice: a tool to distinguish embryonic vs. extra-embryonic gene function
###end article-title 99
###begin article-title 100
###xml 52 59 52 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sox2Cre</italic>
###xml 29 34 <span type="species:ncbi:10090">mouse</span>
###xml 71 76 <span type="species:ncbi:10090">mouse</span>
Efficient gene modulation in mouse epiblast using a Sox2Cre transgenic mouse strain
###end article-title 100
###begin article-title 101
###xml 4 9 4 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
PPARgamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance
###end article-title 101
###begin article-title 102
###xml 59 64 59 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 32 36 <span type="species:ncbi:10090">mice</span>
Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency
###end article-title 102
###begin article-title 103
###xml 27 32 27 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
Effect of heterozygous PPARgamma deficiency and TZD treatment on insulin resistance associated with age and high-fat feeding
###end article-title 103
###begin article-title 104
###xml 26 31 26 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes
###end article-title 104
###begin article-title 105
###xml 85 90 85 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 96 101 92 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 122 127 114 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance
###end article-title 105
###begin article-title 106
###xml 73 78 73 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 87 91 <span type="species:ncbi:10090">mice</span>
Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux
###end article-title 106
###begin article-title 107
###xml 16 21 16 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 44 48 <span type="species:ncbi:10090">mice</span>
Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance
###end article-title 107
###begin article-title 108
###xml 62 67 <span type="species:ncbi:10090">mouse</span>
Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy
###end article-title 108
###begin article-title 109
###xml 20 25 20 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 36 40 <span type="species:ncbi:10090">mice</span>
Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones
###end article-title 109
###begin article-title 110
Muscle-specific Pparg deletion causes insulin resistance
###end article-title 110
###begin article-title 111
###xml 33 38 33 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 59 63 <span type="species:ncbi:10090">mice</span>
Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes
###end article-title 111
###begin article-title 112
###xml 49 54 49 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass
###end article-title 112
###begin article-title 113
###xml 67 72 67 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 76 80 72 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis
###end article-title 113
###begin article-title 114
###xml 4 9 4 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL
###end article-title 114
###begin article-title 115
###xml 47 52 47 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
###end article-title 115
###begin article-title 116
###xml 43 48 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 122 126 <span type="species:ncbi:10090">mice</span>
Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
###end article-title 116
###begin article-title 117
###xml 5 10 5 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation
###end article-title 117
###begin article-title 118
###xml 6 11 6 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
A PPARgamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis
###end article-title 118
###begin article-title 119
###xml 39 44 39 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 129 133 <span type="species:ncbi:10090">mice</span>
Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice
###end article-title 119
###begin article-title 120
###xml 48 53 48 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
Anti-inflammatory and antidiabetic roles of PPARgamma in macrophages
###end article-title 120
###begin article-title 121
Considerations for management of fluid dynamic issues associated with thiazolidinediones
###end article-title 121
###begin article-title 122
###xml 80 85 80 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention
###end article-title 122
###begin article-title 123
###xml 56 61 56 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption
###end article-title 123
###begin article-title 124
###xml 4 9 4 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
PPARgamma in endothelial cells influences high fat diet-induced hypertension
###end article-title 124
###begin article-title 125
###xml 90 95 90 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 131 135 <span type="species:ncbi:10090">mice</span>
Cardiomyocyte-specffic knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice
###end article-title 125
###begin article-title 126
###xml 54 60 <span type="species:ncbi:10090">murine</span>
Differential expression and activation of a family of murine peroxisome proliferator-activated receptors
###end article-title 126
###begin article-title 127
###xml 5 10 5 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
mPPARgamma2: tissue-specific regulator of an adipocyte enhancer
###end article-title 127
###begin article-title 128
###xml 28 33 28 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
Selective disruption of PPARgamma2 impairs the development of adipose tissue and insulin sensitivity
###end article-title 128
###begin article-title 129
###xml 142 147 142 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
The link between nutritional status and insulin sensitivity is dependent on the adipocyte-specific peroxisome proliferator-activated receptor-gamma2 isoform
###end article-title 129
###begin article-title 130
###xml 85 90 85 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 103 107 <span type="species:ncbi:10090">mice</span>
Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPARgamma hypomorphic mice
###end article-title 130
###begin article-title 131
###xml 41 46 41 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 31 36 <span type="species:ncbi:9606">human</span>
Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension
###end article-title 131
###begin article-title 132
###xml 76 81 76 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 92 99 <span type="species:ncbi:9606">patient</span>
A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy
###end article-title 132
###begin article-title 133
PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy
###end article-title 133
###begin article-title 134
###xml 54 59 <span type="species:ncbi:9606">human</span>
Digenic inheritance of severe insulin resistance in a human pedigree
###end article-title 134
###begin article-title 135
###xml 67 72 67 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation
###end article-title 135
###begin article-title 136
###xml 93 98 93 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 73 77 <span type="species:ncbi:10090">mice</span>
Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma
###end article-title 136
###begin article-title 137
###xml 63 68 63 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 78 83 <span type="species:ncbi:10090">mouse</span>
A dominant negative peroxisome proliferator-activated receptor-gamma knock-in mouse exhibits features of the metabolic syndrome
###end article-title 137
###begin article-title 138
###xml 78 83 78 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma
###end article-title 138
###begin article-title 139
Obesity associated with a mutation in a genetic regulator of adipocyte differentiation
###end article-title 139
###begin article-title 140
###xml 31 36 31 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity
###end article-title 140
###begin article-title 141
###xml 15 20 15 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
###end article-title 141
###begin article-title 142
###xml 26 31 26 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity
###end article-title 142
###begin article-title 143
###xml 54 59 54 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer
###end article-title 143
###begin article-title 144
###xml 4 9 4 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
PPARdelta is a very low-density lipoprotein sensor in macrophages
###end article-title 144
###begin article-title 145
###xml 133 137 133 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 138 143 135 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta
###end article-title 145
###begin article-title 146
###xml 4 9 4 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 62 66 58 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
PGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes
###end article-title 146
###begin article-title 147
###xml 137 141 137 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 142 147 139 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 88 93 <span type="species:ncbi:10090">mouse</span>
Growths, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta)
###end article-title 147
###begin article-title 148
###xml 43 47 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;</italic>
###xml 48 53 45 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
###xml 122 126 <span type="species:ncbi:10090">mice</span>
Peroxisome proliferator-activated receptor beta/delta regulates very low density lipoprotein production and catabolism in mice on a Western diet
###end article-title 148
###begin article-title 149
###xml 43 48 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity
###end article-title 149
###begin article-title 150
###xml 61 66 61 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
Regulation of muscle fiber type and running endurance by PPARdelta
###end article-title 150
###begin article-title 151
###xml 43 48 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability
###end article-title 151
###begin article-title 152
###xml 4 9 4 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
PPARdelta regulates glucose metabolism and insulin sensitivity
###end article-title 152
###begin article-title 153
###xml 68 73 68 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy
###end article-title 153
###begin article-title 154
###xml 74 79 74 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#948;</italic>
Transcriptional repression of atherogenic inflammation: modulation by PPARdelta
###end article-title 154
###begin title 155
Figures and Tables
###end title 155
###begin p 156
###xml 0 66 0 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Genetic manipulations of PPARs&#8212;compilation of metabolic phenotypes</italic>
Genetic manipulations of PPARs-compilation of metabolic phenotypes. The scheme synthesizes observations from both whole-body and tissue-specific KOs.
###end p 156

